Last updated: January 12, 2024
Sponsor: Sohag University
Overall Status: Active - Recruiting
Phase
1
Condition
Macular Edema
Diabetic Macular Edema
Diabetic Retinopathy
Treatment
Aflibercept Injection [Eylea]
Ranibizumab Injection [Lucentis]
Clinical Study ID
NCT06205979
Soh-Med-23-12-09MS
Ages 35-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- patients with type II DM and center involving DME with central foveal thickness morethan 280 um.
Exclusion
Exclusion Criteria:
- Evidence of macular ischemia
- Evidence of macular traction
- Previous intravitreal injections
- Previous macular laser therapy
- Previous pars plana vitrectomy
Study Design
Total Participants: 50
Treatment Group(s): 2
Primary Treatment: Aflibercept Injection [Eylea]
Phase: 1
Study Start date:
December 12, 2023
Estimated Completion Date:
June 14, 2024
Connect with a study center
Sohag university Hospital
Sohag,
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.